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Abstract
Changes in endogenous dopamine levels can be detected in humans using positron emis-
sion tomography scans by measuring the amount by which a specific D2/3 radioligand is dis-
placed. In some cases, a challenge drug such as amphetamine is introduced to increase
the amount of dopamine released into the synaptic cleft. Although intravenous amphet-
amine is often utilized, oral amphetamine has been shown to be just as effective in increas-
ing endogenous dopamine levels. Based on our own use of oral amphetamine as a
challenge drug, we have retroactively reviewed our study charts to determine the cardiovas-
cular safety of 0.5 mg kg-1 oral d-amphetamine. Of 172 amphetamine administrations in 144
individuals, only 2.8% of subjects experienced any transient adverse effects. In addition, we
found no clinically relevant differences in increases of vital signs between healthy controls
and patients. We therefore reaffirm the safety of 0.5 mg kg-1 oral amphetamine in subjects
previously screened for cardiovascular risk factors.
Introduction
Over the past two decades, positron emission tomography (PET) and single photon emission
tomography imaging techniques have been used to measure changes in endogenous dopamine
levels in humans. Disturbances in dopamine transmission are implicated in a multitude of neu-
ropsychiatric disorders including drug addiction, schizophrenia, and attention deficit hyperac-
tivity disorder. These fluctuations in extracellular concentrations can be indirectly determined
with PET imaging in vivo by measuring the binding potential of a radiolabeled D2/3 receptor
antagonist before and after a drug challenge [1]. In these specific cases, a drug challenge is
defined as a drug that is known to increase the amount of dopamine released into the synaptic
cleft, such as cocaine, amphetamine, or methylphenidate. This allows researchers to not only
measure differences in baseline dopamine release, but to also determine the extent to which the
increase of dopamine after a drug challenge changes between patient groups.
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Although a potent central nervous system stimulant, the use of amphetamine to increase
extracellular dopamine for PET imaging has been well validated, with acute administrations in
humans considered relatively safe. When comparing oral versus intravenous routes of adminis-
tration however, intravenous amphetamine can lead to rapid changes in cardiovascular vital
signs while the inherently slower absorption of oral amphetamine decreases the risk of induc-
ing unwanted side effects [2–5]. The same applies to oral versus intravenous methylphenidate,
in which the former results in decreased behavioral effects [6]. The administration of oral
amphetamine has been found to be just as effective in modulating dopamine activity when
compared to intravenous amphetamine [2, 5]. Nonetheless, it remains important to reaffirm
the safety of oral amphetamine administrations in humans to ensure there are as few cardiovas-
cular risks to subjects as possible.
Herein the authors retroactively examine the peripheral effects of oral amphetamine across
172 acute administrations performed by the Psychiatric Molecular Imaging Program, Univer-
sity of Pittsburgh in order to confirm the safety of this challenge drug in humans for future
PET imaging studies. To this end, subject charts were reviewed for measures such as blood
pressure (BP) and heart rate (HR) to determine the extent to which amphetamine administra-
tion affects cardiovascular systems.
Methods
The studies included in this analysis were approved by the Institutional Review Board (IRB) of
the University of Pittsburgh Medical Center, and were conducted in accordance with the Bel-
mont Report. For each study, a signed informed consent was obtained from each subject. A
total of 172 subject charts were reviewed for cardiovascular vital sign measurements, which
included BP and HR. Focus was placed on three time-points to make analysis simpler: baseline
(taken prior to amphetamine administration), peak (the highest recording taken after amphet-
amine administration), and discharge (final set of vital signs taken that day). Inclusion criteria
required subjects to have had at least one oral d-amphetamine administration (0.5 mg kg-1). If
a subject received more than one amphetamine administration, all administrations were
counted as separate events.
The following methods pertain to the studies include in the analysis. A physical screening
was conducted to eliminate subjects with a weight greater than 113 kg, a baseline BP above
140/90, and/or those who had an abnormal EKG. On the day of the PET, vital signs were moni-
tored continuously from baseline up to at least 250 minutes post amphetamine administration.
Oral d-amphetamine (Dexedrine) was dispensed to the subject in 2.5 mg pills to equal 0.5 mg
kg-1 of total bodyweight under medical supervision, and the subjects remained under medical
supervision for the remainder of the study. Amphetamine administration occurred 3 hr prior
to the post-amphetamine PET scan. Discharge required subject’s BP to have returned to less
than 20 mmHg above their baseline reading for systolic (SBP) and diastolic BP (DBP) or less
than 150/90 (whichever reading is lower), HR to within 20 beats per min (bpm) of baseline,
and have a normal EKG. Additionally, there could be no remaining subjective effects or con-
tinuing adverse events (as defined by the FDA 21CFR312.32) related to the amphetamine.
The studies incorporated in this analysis include administrations in healthy control partici-
pants (n = 106), as well as patients with attention deficit hyperactivity disorder (n = 6), alcohol-
ism (n = 24), cocaine addiction (n = 6), eating disorders (n = 7), marijuana addiction (n = 10),
and schizophrenia (n = 13). Statistical significance was evaluated by a repeated measures
ANOVA for all data except for mean arterial pressure for which a one-way ANOVA was used.
Both calculations were followed by the Bonferronni post t-test (α = 0.05) and were performed
using SPSS (Armonk, New York).
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Results
Charts were reviewed for 172 administrations of amphetamine in 144 individuals (90 females;
ages 18–55). From this, four subjects (2.8%) were given lorazepam (n = 3, 1–5 mg) or labetalol
(n = 1, 200 mg) for an increased HR, in which all incidents resolved without sequelae. The
highest vital signs observed was a BP of 199/117 in one subject and a HR of 150 bpm in
another. No other amphetamine related adverse events occurred. Of the 144 subjects, several
subjects received more than one amphetamine administration due to the study protocol in
which they were enrolled. The vital signs from these scans were originally included as a
between-subjects factor but they showed no significant difference (SBP: P = 0.577, DBP:
P = 0.432, HR: P = 0.072) and had no major impact on the results. Therefore we chose to report
all 172 administrations as their own unique instance.
Systolic Blood Pressure
A repeated measures ANOVA for baseline, peak, and discharge readings revealed a significant
effect of amphetamine, F(2,170) = 396.8, P< 0.0001. Compared to baseline, the average peak
recording across all subjects increased by 32.7 ± 1.18 mm Hg (P< 0.0001). Discharge was
10.2 ± 1.01 mm Hg higher than baseline for all subjects (P< 0.0001). The average peak
increase did not differ significantly between healthy controls (32.4 ± 1.36 mm Hg, Table 1) and
patients (33.4 ± 2.17 mm Hg) when all patient groups were analyzed together. A comparison of
each patient subtype to the healthy control group revealed no significant differences (Fig 1).
Diastolic Blood Pressure
A repeated measures ANOVA for baseline, peak, and discharge readings revealed a significant
effect of amphetamine, F(2,170) = 372.9, P< 0.0001. Compared to baseline, the average peak
recording across all subjects increased by 22.2 ± 0.85 mm Hg (P< 0.0001). Discharge was
5.23 ± 0.83 mm Hg higher than baseline for all subjects (P< 0.0001). The average peak
increase did not differ significantly between healthy controls (22.4 + 1.11 mm Hg, Table 1) and
Table 1. Oral versus Intravenous Amphetamine in Healthy Subjects.
Oral Amphetamine
(n = 106)
Intravenous
Amphetamine (n = 24)*
Vital Sign Mean SD Mean SD
Systolic blood pressure
Mean baseline (mm Hg) 121.3 10.4 119.5 12.2
Average peak (mm Hg) 153.7 14.9 180.8 18.3
Average time of peak (min) 103.2 54.2 7.4 7.4
Diastolic blood pressure
Mean baseline (mm Hg) 66.8 10.0 71.3 9.4
Average peak (mm Hg) 89.4 10.2 102.5 9.7
Average time of peak (min) 98.8 59.9 7.9 11.2
Heart rate
Mean baseline (mm Hg) 68.1 9.4 64.1 8.7
Average peak (mm Hg) 92.4 17.9 81.4 14.6
Average time of peak (min) 122.8 97.5 18.9 19.0
* Data from Martinez et al., 2007
doi:10.1371/journal.pone.0140647.t001
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patients (21.7 + 1.31 mm Hg) when all patient groups were analyzed together. A comparison of
each patient subtype to the healthy control group revealed no significant differences (Fig 1.)
Heart Rate
A repeated measures ANOVA for baseline, peak, and discharge readings revealed a significant
effect of amphetamine, F(2,170) = 206.8, P< 0.0001. Compared to baseline, the average peak
recording across all subjects increased by 23.6 ± 1.16 bpm (P< 0.0001). Discharge was
10.8 ± 0.96 bpm higher than baseline for all subjects (P< 0.0001). The average peak increase
did not differ significantly between healthy controls (24.4 ± 1.57 bpm, Table 1) and patients
(22.4 ± 1.69 bpm) when all patient groups were analyzed together. A comparison of each
patient subtype to the healthy control group revealed no significant differences (Fig 1).
Mean Arterial Pressure
Mean arterial pressure was calculated using the peak post-amphetamine BP for each subject. A
one-way ANOVA revealed the patients with schizophrenia to have a significantly higher mean
Fig 1. Vital signs on day of PET scan. (A) Systolic blood pressure, (B) diastolic blood pressure, (C) and heart rate at baseline, peak, and discharge time
points for all subjects. (D) Mean arterial pressure during the amphetamine administration for all subjects. Abbreviations: ADHD, attention deficit hyperactivity
disorder; ALC, alcoholism; COC, cocaine addiction; EAT, eating disorders; MAJ, marijuana addiction; SCH, schizophrenia; bpm, beats per minute. *,
P < 0.05 by a one-way ANOVA followed by the Bonferronni post t-test (α = 0.05).
doi:10.1371/journal.pone.0140647.g001
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arterial pressure (118.2 ± 10.6 mm Hg) when compared to healthy controls (108.7 ± 10.9 mm
Hg, P< 0.05, Fig 1). No other statistical significance was found for the remaining patient sub-
groups.
A post hoc comparison of gender revealed males to have a statistically higher SBP than
females at baseline (males = 125.0 ± 8.6 mm Hg, females = 116.9 ± 15.5 mm Hg, P< 0.0001,
Fig 2), peak (males = 162.7 ± 15.2 mm Hg, females = 145.1 ± 11.7 mm Hg, P< 0.0001, Fig 2),
and discharge (males = 135.74 ± 11.0, females = 126.6 ± 11.0, P< 0.0001, Fig 2) measurements.
In addition, males had a higher DBP than females at baseline (males = 69.8 ± 9.5 mm Hg,
females = 65.4 ± 10.4 mmHg, P< 0.01, Fig 2) and peak (males = 93.7 ± 11.5 mm Hg,
females = 86.1 ± 8.9 mm Hg, P< 00001, Fig 2) measurements. There were no differences in
HR between genders at any time point.
Discussion
Our results confirm that administration of oral amphetamine (0.5 mg kg-1) during a PET imag-
ing study is safe in persons who have been previously screened for cardiovascular risk factors.
Other than a small percentage of subjects who experienced transient adverse events, the major-
ity of subjects displayed a typical peripheral response to the stimulant. Nonetheless, it is imper-
ative that future subjects be monitored closely for changes in cardiovascular vital signs when
exposed to any amphetamine dose.
Many groups have utilized either oral methylphenidate or amphetamine for the purpose
of measuring changes in dopamine release, however only a few groups have included
changes in vital signs in their results. Nonetheless, the extant literature reveals similar
increases in peripheral vital signs in healthy control subjects at comparable time points to
our studies. Administration of 0.5 mg kg-1 oral amphetamine to subjects (n = 8) resulted in a
peak SBP of approximately 150 mm Hg 2 hr post dosing [7]. In a similar fashion, 30 mg oral
amphetamine (n = 12) led to an average increase in SBP from baseline of 20 ± 2.1 mm Hg 2
hr post administration [2], while intake of either 25, 30, or 35 mg (0.38–0.45 mg kg-1) oral
amphetamine (n = 9) increased SBP by 17 ± 2.5 mm Hg when measured 90 min post
Fig 2. Gender differences in systolic blood pressure. Systolic blood pressure readings frommales (black
bars) and females (white bars) across three separate measurements. The analysis includes both healthy
controls and patients. *, P < 0.0001 by a repeated measures ANOVA followed by the Bonferronni post t-test
(α = 0.05).
doi:10.1371/journal.pone.0140647.g002
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administration [8]. These results are in agreement with our observed changes in SBP, which
suggests good reproducibility in the vital signs of healthy controls in response to oral
amphetamine.
Comparatively, intravenous injections of amphetamine have resulted in higher increases in
BP in a shorter amount of time. In healthy controls, administration of 0.3 mg kg-1 amphet-
amine raised mean SBP by 42 ± 1.6 mm Hg (n = 8) [9], 43 ± 13 mm Hg (n = 7) [10], 61.3 ± 2.2
mmHg (n = 24) [11], and 41 ± 14 mm Hg (n = 15) [12]. Similar increases were also observed
in cocaine patients (59.7 ± 2.1 mmHg, n = 24) [11] and schizophrenics (36 ±12 mm Hg;
n = 15) [12]. Where reported, peak increases in SBP occurred within 25 min after injection
compared to 102.2 ± 53.3 min after oral administration in our studies. Of these studies, Marti-
nez and colleagues provided the most comprehensive data on the effects of intravenous
amphetamine on vital signs, to which we have compared our healthy control data (Table 1)
[11]. From this it is clear that oral amphetamine results in a lower peak in systolic and DBP
across a longer period of time compared to intravenous amphetamine.
An earlier study conducted by our group found that 24 administrations of 0.5 mg kg-1 oral
amphetamine in 12 healthy controls resulted in a mean peak SBP of 160 ± 13 mm Hg [5]. In
the recently expanded cohort of n = 144 administrations, we observed the mean peak SBP to be
slightly lower (153.5 ± 16.1 mmHg). This further highlights the safety of oral amphetamine
given that we possess data from a large cohort, which includes multiple patient subtypes. How-
ever the administration of amphetamine to individuals that have been screened for cardiovas-
cular health is not without risk. Four subjects did receive medical intervention for a prolonged
increased HR (HR did not return to less than 20 bpm from baseline at time of discharge).
These subjects were given either labetelol or lorazepam, and remained under medical supervi-
sion until their HR returned to baseline. Subsequently they returned for a follow-up in which
their vital signs and EKG were found to be normal. Although four subjects is a small percentage
of the total number of participants (144), it still emphasizes the need for medical supervision
when performing amphetamine challenge studies.
One limitation of this study was the number of variables used to determine cardiovascular
safety after amphetamine administration. This limits our definition of “cardiovascular safety”
to refer only to HR, BP, and cardiac rhythm documented with an EKG (performed at a single
time point prior to discharge). For example, we cannot rule out the fact that abnormal cardiac
rhythm may have been documented more often if we had performed continuous Holter Moni-
toring in subjects following amphetamine administration. In addition, we did not include data
on subject’s subjective response after amphetamine. This data set is comprised of vital sign
recordings from several different protocols, not all of which included surveys or questionnaires
to capture the psychological (subjective) experiences of amphetamine in individuals. Neverthe-
less, none of the subjects reported any subjective adverse events (neurological or cardiac) that
required medical intervention. We were also unable to detect any differences in peripheral
response to amphetamine between patient sub-groups. Although this is not all that surprising,
especially given a relatively low “n” for some groups, a recent study reported abnormal cardio-
vascular responses to oral amphetamine (0.4 mg/kg) in pathological gamblers (n = 12) as com-
pared to healthy controls [13].
Based on the multitude of amphetamine administrations performed in our lab and others,
we conclude 0.5 mg kg-1 oral amphetamine to be safe for the purpose of conducting PET imag-
ing studies in healthy controls and patients who have been carefully screened to eliminate
physiologic risk factors. Further research utilizing oral amphetamine (or methylphenidate)
during PET imaging scans are crucial for understanding differences in dopamine transmission
between patients and healthy controls, and the hope is that future groups will implement this
Safety of Oral Amphetamine during PET
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paradigm with the knowledge that 0.5 mg kg-1 amphetamine can be administered safely under
medical supervision.
Supporting Information
S1 Table. Raw data of vital signs. Systolic blood pressure, diastolic blood pressure, and MAP
data for the attention deficit hyperactivity disorder (ADHD), alcoholism (ALC), cocaine addic-
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controls (CTR).
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